Physician profile
Mark Hershowitz
NPI 1275530834
$1,571.68
in general payments reported to CMS, 2019-2025
13 companies · $471 in 2025
The $471 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.13 · 2022: $296 · 2023: $261 · 2024: $471 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.78 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $249.42 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $224.95 | 2022-2025 | Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $172.81 | 2022-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $121.93 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $121.73 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $80.84 | 2021-2022 | |
| Amgen INC. | $46.61 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $34.20 | 2021 | |
| Tearlab Corp | $21.93 | 2023 | Tearlab Osmolarity System |
| Dompe US, INC. | $20.90 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $15.57 | 2021 | |
| Biotissue Holdings INC. | $14.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hershowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.